Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Nivolumab for treating resectable (tumours ≥4 cm or node positive) non-small-cell lung cancer

5 October 2026

Condition

Cancer

-

Published on 05 Oct 2026
Last Updated on 05 Oct 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Nivolumab 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL concentrate for solution for infusion when used in combination with platinum-doublet chemotherapy for neoadjuvant treatment of resectable (tumours ≥4 cm or node positive) non-small-cell lung cancer. Maximum treatment duration: 3 cycles.

The decision was based on acceptable clinical effectiveness and pricing proposal by the company.

Funding Status

Nivolumab 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 December 2026.

Clinical indication, subsidy class and MediShield Life claims eligibility for nivolumab are provided in the Annex.

Nivolumab for treating resectable (tumours ≥4 cm or node positive) non-small-cell lung cancer (Published 05 Oct 2026) [PDF, 243.45 KB] (opens in new tab)